Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending May 2011. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of April 28, 2011:
- Total issued Ordinary shares (25p each): 5,656,531,573
- Shares held in Treasury: 493,224,284
- Total voting rights: 5,163,307,289
No material changes to financial performance or operational status are reported in this specific filing.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of share capital and voting rights.
Investor Verification Checklist
- Verify the total number of voting rights (5,163,307,289) for compliance with Financial Services Authority Disclosure and Transparency Rules.
- Confirm the number of shares held in Treasury (493,224,284) as of April 28, 2011.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.